Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6916 to 6930 of 8213 results

  1. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued Reference number: GID-TA10033

    Technology appraisal guidance
    Discontinued

  2. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued Reference number: GID-TA10045

    Technology appraisal guidance
    Discontinued

  3. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

    Technology appraisal guidance
    Discontinued

  4. Zio XT for detecting cardiac arrhythmias

    In development Reference number: GID-MT591 Expected publication date: TBC

    Medical technologies guidance
    In development

  5. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

    Medical technologies guidance
    In development

  6. Surgical vessel sealing systems (MT798)

    In development Reference number: GID-MT594 Expected publication date: TBC

    Medical technologies guidance
    In development

  7. SILK artery reconstruction device (discontinued)

    Discontinued Reference number: GID-MT81

    Medical technologies guidance
    Discontinued

  8. Personal, social, health and economic education focusing on sex and relationships and alcohol education

    Discontinued Reference number: GID-PHG0

    NICE guideline
    Discontinued

  9. Maternal health: promoting maternal health through community based strategies

    Discontinued Reference number: GID-QS10016

    Quality standard
    Discontinued

  10. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

    Technology appraisal guidance
    Discontinued

  11. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued Reference number: GID-TA10236

    Technology appraisal guidance
    Discontinued

  12. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued Reference number: GID-TA10242

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued Reference number: GID-TA10243

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued Reference number: GID-TA10244

    Technology appraisal guidance
    Discontinued

  15. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued